Radical Cystectomy Workup

Updated: Nov 27, 2016
  • Author: Michael Christopher Large, MD; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print

Laboratory Studies

See the list below:

  • Urinalysis

    • Urinalysis is used to identify or to confirm microscopic or gross hematuria. When hematuria is present along with bacteruria or pyuria, obtain a urine culture to rule out urinary tract infection.

    • Urinalysis may yield false-negative results because hematuria associated with bladder cancer is often intermittent.

  • Urine cytology

    • Exfoliated urothelial cells are viewed using microscopy. In some urothelial cancers, cellular clumping, a high nuclear-to-cytoplasmic ratio, nucleoli, and atypia are seen.

    • Avoid the first morning sample because of cellular degeneration.

    • Cytology is useful for identifying CIS and high-grade tumors but is less useful for low-grade tumors.

    • The sensitivity of cytology for grades 1, 2, and 3 disease is 20%, 50%, and 90%, respectively.

    • Tests that are used to assess for protein (NMP22), nucleic acid, or chromosomal abnormalities (chromosomes 3, 7, 9, 17) are emerging as possible urine-based adjuncts for the diagnosis of bladder cancer.

  • Bladder barbotage

    • Bladder barbotage consists of repeated washings of bladder urothelium with normal saline.

    • This test has better sensitivity than urine cytology because the total yield of cells is higher.

  • Liver function tests and bony fraction of alkaline phosphatase: These tests are used to evaluate for metastatic spread to liver and bone.


Imaging Studies

See the list below:

  • An appropriate evaluation of hematuria includes radiographic (CT scanning, ultrasonography, retrograde pyelography, intravenous pyelography [IVP]) or direct imaging (cystoscopy, ureteroscopy) of the entire urinary tract. A standard hematuria evaluation includes (1) CT scanning of the abdomen and pelvis, with and without intravenous contrast, often termed CT urography and (2) flexible cystoscopy. If a patient cannot receive intravenous contrast, the evaluation commonly consists of renal ultrasonography, cystoscopy, and retrograde ureteropyelography.

  • CT scanning and ultrasonography can reveal filling defects or masses in the urinary tract; however, they are frequently unable to demonstrate small urothelial tumors.

  • A bone scan is indicated if the patient has symptomatic bone pain, elevated calcium levels, or elevated alkaline phosphatase levels.

  • MRI is used in some centers for evaluation of both local and metastatic disease; however, its staging accuracy is unknown. Therefore, the use of MRI is currently under investigation.

  • Ferumoxtran-10–enhanced MRI and 11C-choline positron emission tomography/CT are under investigation as potential modalities for improving preoperative nodal staging. [6, 7]


Other Tests

See the list below:

  • Upon recognition of disease that may prove amenable to radical cystectomy, preoperative staging is essential for stratifying the chance of disease eradication and recurrence risk, as well as for identifying patients with metastatic foci who are not candidates for surgery. Preoperative staging involves the following:

    • The patient is examined under anesthesia to determine if the mass is fixed (pT4) or mobile. In women, this includes a bimanual pelvic examination; in men, this includes a bimanual examination with one hand per rectum and the other on the lower abdominal wall.

    • CT scanning of the abdomen and pelvis is performed. Both overstaging (20%) and understaging (50%) are common if only one study is performed.

    • Chest radiography is performed to assess for metastatic deposits.


Diagnostic Procedures

See the list below:

  • Biopsy - Transurethral resection of bladder tumor

    • The biopsy consists of cystoscopic resection of tumors with biopsy forceps or a resectoscope. Superficial-appearing papillary tumors, as assessed by an experienced urologist, are virtually always noninvasive lesions. As a rule, any lesion that may extend into the lamina propria or deeper should include deep resection specimens that incorporate muscularis propria.

    • The biopsy can be performed in an operating room under general or spinal anesthesia.

    • The site, size, and number of tumors and whether papillary tumors are sessile, solid, nodular, or pedunculated is documented.

    • A biopsy of the prostatic urethra may be considered in patients at high risk for urethral disease (extensive CIS, multifocal high-grade disease, disease at or near the bladder neck, an abnormal-appearing prostate); 10%-40% of patients with bladder cancer have prostatic urethral involvement.


Histologic Findings

In the United States, 90% of bladder cancers are TCC, 5% are SCC, and 2% are adenocarcinoma. Grades 1, 2, and 3 refer to well, moderately, and poorly differentiated microscopic classifications, respectively. Forty percent of newly diagnosed bladder cancers are high grade, and up to half of these are stage T2 or higher. [8, 9]



Upon diagnosis of bladder cancer, accurately staging the cancer is essential for instituting appropriate therapy.

Table 1. Staging of Bladder Cancer (Open Table in a new window)

Disease Type



Superficial disease


Confined to mucosa


Involving lamina propria and muscularis mucosa


Malignant cells still confined to the flat urothelial layer

Muscle-invasive disease


Invasion of muscularis propria


Extension into perivesical fat


Invasion of pelvic sidewall or adjacent organs or metastatic disease

Lymph node stages include the following:

  • NX - Unknown lymph node status

  • N0 - No lymph node involvement

  • N1 - A single lymph node in the true pelvis

  • N2 - Two or more lymph nodes in the true pelvis

  • N3 - Lymph nodes along the common iliac artery or beyond